Boston biotech firm R3 BIO is developing lab-grown organ systems called "bodyoids" with investors hoping the technology could ...

A research team at NYU Langone Health and Sage Bionetworks has been awarded a $25 million grant to establish the data hub and coordinating center for the National Institutes of Health's ...

-- EPA’s ToxCast ™ evaluation of the developmental toxicity risk of 1,065 compounds using Stemina’s devTOX quickPredict test (devTOXqP) published in Toxicological Sciences -- devTOXqP is the only ...

R3 Bio has a bold idea for replacing lab animals: genetically-engineered whole organ systems that lack a brain. The long-term ...

Support organoid research with scalable human-based systems that enhance reproducibility and accelerate breakthroughs in ...

Animal studies often fail to predict human tissue responses to new drugs or newly developed therapies. Besides generating ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing ...

In April of this year, the Food and Drug Administration (FDA) announced a new roadmap that aims to replace animal testing in the development of new drugs with more human-relevant methods. The goal is ...

As the FDA released its draft guidance, the NIH said it will invest $150 million in human-based research to develop the tools ...

Federal regulators in the United States are pushing harder than ever to reduce and eventually replace animal testing in drug ...

The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in ...